Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) EBIT: 2021-2023

Historic EBIT for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$45.5 million.

  • Cullinan Therapeutics' EBIT fell 39.49% to -$45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$191.1 million, marking a year-over-year decrease of 232.11%. This contributed to the annual value of -$196.9 million for FY2024, which is 3.05% down from last year.
  • According to the latest figures from Q4 2023, Cullinan Therapeutics' EBIT is -$45.5 million, which was down 0.53% from -$45.2 million recorded in Q3 2023.
  • Cullinan Therapeutics' EBIT's 5-year high stood at $239.7 million during Q2 2022, with a 5-year trough of -$62.8 million in Q1 2023.
  • In the last 3 years, Cullinan Therapeutics' EBIT had a median value of -$32.6 million in 2022 and averaged -$9.5 million.
  • Examining YoY changes over the last 5 years, Cullinan Therapeutics' EBIT showed a top increase of 1,543.50% in 2022 and a maximum decrease of 2,480.25% in 2022.
  • Over the past 3 years, Cullinan Therapeutics' EBIT (Quarterly) stood at -$34.3 million in 2021, then increased by 5.06% to -$32.6 million in 2022, then slumped by 39.49% to -$45.5 million in 2023.
  • Its EBIT was -$45.5 million in Q4 2023, compared to -$45.2 million in Q3 2023 and -$37.6 million in Q2 2023.